Venuto Charles S, Herbst Konnor, Chahine Lana M, Kieburtz Karl
medRxiv. 2025 Mar 7:2024.08.07.24311578. doi: 10.1101/2024.08.07.24311578.
To develop and externally validate models to predict probabilities of alpha-synuclein (a-syn) positive or negative status in vivo in a mixture of people with and without Parkinson's disease (PD) using easily accessible clinical predictors.
Uni- and multi-variable logistic regression models were developed in a cohort of participants from the Parkinson Progression Marker Initiative (PPMI) study to predict cerebrospinal fluid (CSF) a-syn status as measured by seeding amplification assay (SAA). Models were externally validated in a cohort of participants from the Systemic Synuclein Sampling Study (S4) that had also measured CSF a-syn status using SAA.
The PPMI model training/testing cohort consisted of 1260 participants, of which 76% had manifest PD with a mean (± standard deviation) disease duration of 1.2 (±1.6) years. Overall, 68.7% of the overall PPMI cohort (and 88.0% with PD of those with manifest PD) had positive CSF a-syn SAA status results. Variables from the full multivariable model to predict CSF a-syn SAA status included age- and sex-specific University of Pennsylvania Smell Identification Test (UPSIT) percentile values, sex, self-reported presence of constipation problems, leucine-rich repeat kinase 2 ( ) genetic status and pathogenic variant, and status. Internal performance of the model on PPMI data to predict CSF a-syn SAA status had an area under the receiver operating characteristic curve (AUROC) of 0.920, and sensitivity/specificity of 0.881/0.845. When this model was applied to the external S4 cohort, which included 71 participants (70.4% with manifest PD for a mean 5.1 (±4.8) years), it performed well, achieving an AUROC of 0.976, and sensitivity/specificity of 0.958/0.870. Models using only UPSIT percentile performed similarly well upon internal and external testing.
Data-driven models using non-invasive clinical features can accurately predict CSF a-syn SAA positive and negative status in cohorts enriched for people living with PD. Scores from the UPSIT were highly significant in predicting a-syn SAA status.
利用易于获取的临床预测指标,开发并进行外部验证模型,以预测帕金森病(PD)患者和非PD患者混合群体体内α-突触核蛋白(a-syn)阳性或阴性状态的概率。
在帕金森病进展标志物倡议(PPMI)研究的参与者队列中开发单变量和多变量逻辑回归模型,以预测通过种子扩增测定(SAA)测量的脑脊液(CSF)a-syn状态。在系统突触核蛋白采样研究(S4)的参与者队列中对模型进行外部验证,该队列也使用SAA测量了CSF a-syn状态。
PPMI模型训练/测试队列由1260名参与者组成,其中76%患有明显的PD,平均(±标准差)病程为1.2(±1.6)年。总体而言,PPMI队列中68.7%(患有明显PD的患者中88.0%)的CSF a-syn SAA状态结果为阳性。预测CSF a-syn SAA状态的完整多变量模型中的变量包括宾夕法尼亚大学嗅觉识别测试(UPSIT)按年龄和性别划分的百分位数、性别、自我报告的便秘问题、富含亮氨酸重复激酶2( )基因状态和致病变异以及 状态。该模型在PPMI数据上预测CSF a-syn SAA状态的内部性能在受试者工作特征曲线下面积(AUROC)为0.920,敏感性/特异性为0.881/0.845。当将该模型应用于外部S4队列时,该队列包括71名参与者(70.4%患有明显PD,平均病程5.1(±4.8)年),其表现良好,AUROC为0.976,敏感性/特异性为0.958/0.870。仅使用UPSIT百分位数的模型在内部和外部测试中表现同样良好。
使用非侵入性临床特征的数据驱动模型可以准确预测富含PD患者群体中CSF a-syn SAA的阳性和阴性状态。UPSIT得分在预测a-syn SAA状态方面具有高度显著性。